HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MDLN
Medline Inc.
MDLN's fundamentals are mixed: revenue grew 13%, but its operating margin fell 3 points to 5.7%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MDLN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Healthy | |
| Weak |
MDLN's profitability and cash flow are currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MDLN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 33x | $22.09 | -45% |
| Fair | 40x | $27.00 | -32% |
| Expensive | 42x | $28.23 | -29% |
| Current | 60x | $39.98 | — |
Historical ranges are pointers, not guarantees.
MDLN's PE is 60x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MDLN Forward outlook
There aren't enough analyst estimates for MDLN to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MDLN Earnings Per Share
MDLN and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MDLN in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MDLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.9B | +10% |
| Q2 2026 | $7.7B | +12% |
| Q1 2026 | $7.4B | +11% |
| Q3 2025 | $7.1B | +11% |
| Q2 2025 | $6.9B | +11% |
MDLN's revenue has grown year over year every quarter since late 2025: $7.9B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.4% | -1.7 points |
| Q2 2026 | 5.1% | -4 points |
| Q1 2026 | 5.7% | -3.2 points |
| Q4 2025 | 5.5% | N/A |
| Q3 2025 | 8.1% | -0.9 points |
| Q2 2025 | 9.1% | +0.8 points |
| Q1 2025 | 8.9% | N/A |
| Q3 2024 | 9% | N/A |
MDLN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
MDLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $884M | +65% |
| Q2 2026 | $604M | +486% |
| Q1 2026 | $316M | -41% |
| Q3 2025 | $535M | -13% |
MDLN has the edge over HIMS in the latest year-over-year cash flow comparison.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MDLN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MDLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +53% | +455M shares |
| 1 year | +67% | +529M shares |
MDLN has 1.3B diluted shares, up 67% from a year ago, despite $2B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $2B |
| Q3 2025 | $18M |
| Q2 2025 | $3M |
| Q1 2025 | $18M |
| Q3 2024 | $3M |
MDLN spent $2B buying back its own shares over the past year.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MDLN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 4.0x | High |
| Q2 2026 | 3.9x | Elevated |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.6x | Elevated |
MDLN's net debt is about 4.0 years of its operating earnings (EBITDA).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MDLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.9 | Neutral |
| Stochastic | 53.6 | Neutral |
MDLN's weekly RSI is 57 (neutral) and its Stochastic is 54 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MDLN PE vs Healthcare Sector
| Metric | MDLN | Sector median | Relative |
|---|---|---|---|
| PE | 60x | 26x | 131% above |
MDLN is trading at 60x earnings, a 131% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
MDLN has stronger trend alignment. HIMS is above 0 of 5 weekly averages versus MDLN above 2 of 2.
MDLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.1 | 11% above |
| 20 week MA | $36.6 | 9.3% above |
MDLN is in an uptrend: it's above all two of its weekly moving averages, and 9.3% above its 20-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MDLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $41.7 | $44.1 | +6% |
| 2026 YTD | $44.1 | $40.0 | -9.4% |
MDLN has the edge over HIMS on returns for 2026, with the stronger performance.